lizzy241, Vascepa is a drug that will have to use sales reps, especially
in Europe, to get doctors to write scrips. Ideally, the sales reps will
have long standing relationships with doctors in the Cardiovascular field.
In Europe there is no DTC advertising so the system there uses key opinion
leaders to pass down information about the drug. This is why GIA is folly.
(Especially in Europe.) Could Amazon play a role? Maybe...far into the
future. I certainly hope there is at least one BP out there with strong
distribution in Europe who understands the potential Vascepa has for
Europe and the ROW. Whatever the solution to a US launch of generics
I would let the BP acquirer figure out what is best for them. JT took
his shot and missed. As usual JT is blindsided by events once again
seemingly without a game plan to recover. Time for BP (the professionl
players) to called into the arena. I'm certain they will be able to
figure it out.
News 
Market Data 
Discover 
